EP1830787A1 - Association d'extraits vegetaux à base de groseille maquereau, d'orchidee noire et de tulipe noire et composition topique comprenant l'association de ces extraits végétaux - Google Patents
Association d'extraits vegetaux à base de groseille maquereau, d'orchidee noire et de tulipe noire et composition topique comprenant l'association de ces extraits végétauxInfo
- Publication number
- EP1830787A1 EP1830787A1 EP05775497A EP05775497A EP1830787A1 EP 1830787 A1 EP1830787 A1 EP 1830787A1 EP 05775497 A EP05775497 A EP 05775497A EP 05775497 A EP05775497 A EP 05775497A EP 1830787 A1 EP1830787 A1 EP 1830787A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- association
- black
- skin
- topical composition
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present invention relates to an association based plant extracts of gooseberry, black orchid and black tulip, and a topical composition containing it, and more particularly a composition containing such an association, useful for the treatment and the prevention of damage related to the aging of the skin, as well as the associated cosmetic processes.
- the skin has several integrated layers, ranging from the superficial layer, the epidermis, to the deeper layers, the dermis and the hypodermis, and each has specific properties allowing the whole to react and adapt to conditions of its environment.
- the epidermis is mainly composed of three types of cells which are keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells.
- the epidermis which constitutes the outer layer, plays a fundamental role in ensuring the protection and maintenance of good trophicity. This is why many compositions have been developed to protect and improve its functions, including strengthening its elasticity and firmness.
- the dermis is thick, solid, rich in nerves and blood vessels and sweat glands. It protects and repairs damaged tissues. This layer consists mainly of collagen, elastin and proteoglycans. These three types of molecules are synthesized by dermal fibroblasts. Collagen fibers, which represent 70% of the dry weight of the dermis, form a support network responsible for the mechanical characteristics of the skin such as strength and texture.
- Elastin is responsible for elasticity and proteoglycans play a major role in structure and hydration of the skin.
- Other cells such as macrophages and leucocytes are also present in the dermis layer.
- the hypodermis attached to the bottom of the dermis, is the deepest layer of the skin. It contains lipid-producing fat cells to produce a fat layer that protects the muscles, bones, and internal organs from shock, and acts as an insulator and energy source during periods of time. young.
- One of the first signs of skin aging is a loss of elasticity and the formation of fine lines and wrinkles, which are a direct result of the deterioration of the dermis layer of support.
- the ability of the skin to replace damaged collagen decreases and more spaces and irregularities develop in the collagen network.
- the appearance of pigment marks, the fineness of the skin and the sagging of the skin are also changes observed during the subsequent aging of the skin.
- Many factors contribute to accelerating the breakdown of collagen particularly sun exposure, free radicals, certain hormonal changes associated with old age, and tobacco.
- the aging of the skin is often described as appearing in two ways. The first is chronological or intrinsic aging, while the second is extrinsic aging, namely aging caused by the environment; this is particularly the case of photoaging, which is the damage done to the skin because of the direct or indirect effects of ultraviolet light.
- the present invention relates not only to intrinsic aging, but also to extrinsic aging.
- aging causes in particular a decrease in protein synthesis (collagen, elastin) a decrease in the synthesis of proteoglycans among others, as well as an elevation of metalloproteinases of MMP3 type.
- oxidation phenomena free radical content
- Collagen implants have also been proposed to conceal expression lines around the eyes or mouth, dermabrasion and chemical peels to remove the upper layer of damaged skin, cosmetic surgery, such as blepharoplasty (surgical procedures).
- Patent application WO 02069992 lists a large number of plant extracts obtained under particular conditions where the plant is previously subjected to stress, and likely to provide an inhibitory effect of certain extracellular proteases and consequently to limit the effects harmful to these proteases.
- the use of certain plant extracts in cosmetic compositions is also described in patent applications JP 02279618 relating to water-soluble extracts of orchid with moisturizing action, JP 2003040758 relating to extracts of saxifrage and JP 10007582 relating to extracts of tulip.
- the subject of the present invention is therefore an association of vegetable extracts based on gooseberry, black orchid and black tulip.
- the present invention also relates to a topical composition for the treatment or prevention of damage related to aging of the skin, comprising an association according to the first subject of the invention indicated above.
- the invention also aims to propose the use of an association as above, for the preparation of a topical composition for combating skin aging damage.
- the subject of the present invention is also a cosmetic process for combating skin aging damage, which comprises the step of applying to a region of the affected skin a composition containing an effective amount of the topical composition according to the second object of the present invention.
- the cosmetic process for improving the external appearance comprising a step of applying this topical composition to the areas of the affected skin is also another object of the present invention.
- These topical compositions can advantageously be used in dermatology or cosmetology for the treatment or prevention of damage associated with aging of the skin, more particularly including the loss of skin firmness and tone, and the appearance of wrinkles. and fine lines.
- the topical composition is useful for dermatological or cosmetic purposes, unless otherwise indicated.
- the gooseberry is particularly known for its high content of polyphenols (RIBES UVA CRISPA).
- the gooseberry in Maquereau originates from Asia and has become sub-spontaneous in Northern and Eastern Europe. It is found in plain or low mountain colonizing poor environments or even specifically acidic terrains. For example it is found in the Vosges up to 1000 m altitude and on the banks of the Loire in flood zone. It is the fruit that is used.
- the Black Orchid Cycnoches Cooperi
- like all orchids lives in poor conditions and pine bark or debris of lichen may be sufficient for its development.
- the Black Orchid is particularly rich in flavonoids which have a particular interest as scavengers of free radicals and protectors meinbranaires. It is the whole plant that is used.
- the Black Tulip (Tulipa Nigra) is the plant that contains the most plant DNA. It is a cultivated tulip. Its origin in the mountainous regions of northern Europe and Asia explains its great qualities of resistance and repro ⁇ duction, as well as a great resistance to UV. It is an extract of the petals that is used. These plant extracts can be characterized by their dry extract content and / or by their active content.
- the extracts are advantageously hydro-glycol or hydro-alcoholic extracts, for example obtained by cold maceration in a water / propylene glycol or water / ethanol mixture.
- the extracts detailed below may be used for the preparation of the combination according to the present invention.
- the combination may also take the form of oily extracts that can be obtained by macerating the plants in capric triglycerides / caprylic, oleic sunflower or any polar / apolar mixture of the type of apricot kernel oil / Vaseline oil. It is thus possible to extract liposoluble materials such as flavones and certain polyphenols.
- the topical compositions according to the invention may be in any cosmetic formulation.
- the topical compositions according to the invention may for example comprise excipients suitable for external topical administration, in particular excipients dermatologically acceptable.
- excipients suitable for the formulation include in particular thickeners such as natural gums and synthetic polymers; emollients and surfactants such as cetearyl octanoate, isopropyl myristate, cetearyl isononanoate, dimethicone, cyclomethicone, polyglyceryl 3-diisostearate, hydrogenated polyisobutene, cetyl alcohol cetyl palmitate, cetyl phosphate; emulsifiers; preservatives such as phenoxyethanol, methyl parahydroxybenzoate (methyl paraben), propylparaben parahydroxybenzoate and Phenonip® associating phenoxyethanol and methyl, ethyl, butyl and isobutyl parahydroxybenzoates; dyes; the perfumes ; etc.
- thickeners such as natural gums and synthetic polymers
- emollients and surfactants such as cetearyl octanoate, iso
- compositions may be used in the compositions: moisturizing agents such as propylene glycol, glycerol, butylene glycol and also antioxidant vitamins such as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols.
- Skin conditioning agents such as nylon can also be added to the composition.
- the topical compositions according to the invention may be in the form of a solution, a hydrophilic lotion, an ointment, a cream, a serum or a gel.
- the compositions may also be, for example, in the form of oil-in-water, water-in-oil or multiple emulsions, foaming products or in the form of liposomes.
- each of the vegetable extracts of gooseberry, black orchid and black tulip is advantageously present in a content of between 5 and 90%, these contents being expressed relative to total weight of the association.
- these contents are approximately 25 to 50%, and more preferably an association comprising the three extracts in substantially equal amounts is used.
- the topical compositions according to the invention typically comprise between 0.1% and 20% (w / w) by weight of the combination according to the present invention relative to the total weight of the topical composition, and preferably from 2% to 8% by weight. %.
- the extracts constituting the combination of the invention are supplemented with active ingredients or auxiliary ingredients chosen for their complementary properties, in order to reinforce the anti-aging effects of the composition.
- Imperata cylindrica for example MOIST 24® from Sederma
- an antihyaluronidase such as Echinacin B in order to generate a maximum of bound water, of Imperata cylindrica, for example MOIST 24® from Sederma
- amaranth seed protein Amarantus caudatus
- pea globulins to obtain a skin tightening effect
- Calophylum oil to enhance the effect anti-wrinkles
- Echium oil for its anti-inflammatory effect or palmitoyl pentapeptide-3
- Matrixyl® or derivatives such as palmitoyl GHK (having the glycyl-Histidyl-Lysine chain) and the palmitoyl GQPR (Glycyl-Glutamyl-Prolyl-Arginine) or palmitoyl VGVAPG (Valyl-Glycyl-Valyl-
- the topical compositions according to the invention have an effect of improving cutaneous damage due to aging.
- the first results can be obtained after 2 to 3 weeks of daily treatment by applying the compositions once or twice a day to the areas of the skin to be treated.
- Said compositions of the invention may be chosen for day and / or night use on the face, body and hands.
- the compositions according to the invention are particularly suitable for the treatment of the contour areas of the eyes and lips, which are very fragile and highly susceptible to the appearance of wrinkles and loss of firmness of the skin.
- the compositions according to the invention are very well tolerated on this sensitive area, and make possible a visible reduction in the number of wrinkles and marks on the eyes, as well as a particularly sensitive skin firming of the eye and mouth contours.
- Example 5 relates to a toxicological study and to tests of activity on human fibroblasts, which made it possible to evaluate the anti-inflammatory effect (interleukins) and the anti-aging effect (MPP3 assay, proteoglycans and collagens).
- the "plant complex” corresponds to an association based on vegetable extracts of gooseberry, black orchid and black tulip according to the present invention in which the three extracts are those detailed. above (extracted by cold maceration of a mixture of water / propylene glycol or water / ethanol) and they are included in equal parts. Unless otherwise indicated, the compositions are given in parts by weight.
- Example 4 Regenerating anti-wrinkle serum Mixture of lyophilized plants: - Polyphenols of Currant Mackerel 0.05 - Orchid Extract 0.10 - DNA of Black Tulip 0.20 - Glycocolin Q, 65 TOTAL 1.00 In lyophilized vial Solvent Glycerin 0, 5 - Butylene glycol 0.5 Biosaccharide grum-1 1.0 - Phenonip 0.07 - Pea Globulins 2.0 Imperata cylindrica extract 0.3 Amaranth Proteins 1.0 - Demineralized Water QSP 10.0 The lyophilized portion is dissolved by the solvent and provides a treatment for 7 days.
- Example 5 In addition to the toxicology of the product, studies on human fibroblasts in culture were conducted.
- fibroblasts in culture The fibroblast cultures are established from human foreskin skin harvested during circumcisions and are amplified in RPMI 1640 culture medium supplemented with fetal calf serum, L-glutamine and gentamycin. The fibroblasts were seeded in boxes of 25 cm 2 at a rate of 10 ⁇ cells per ml. They were then incubated for 24 hours.
- Toxicological aspect The purpose of this first step was to seek the cytotoxicity of the product with respect to human fibroblasts in culture. The cell growth is carried out on 3 non-cytotoxic concentrations. Cytotoxicity was achieved by determining neosynthesis of proteins.
- Human fibroblasts obtained by primoculture were recovered after trypsinization and centrifugation.
- the cell pellet was resuspended in 10 ml of RPMI 1640 medium supplemented with fetal calf serum (10%), L-glutamine (8 mM) and gentamicin (80 ⁇ g / ml).
- the cells were distributed in multiwell plates (6 wells) at a rate of 1.10 5 cells / ml. The plates were incubated for 24 hours. The medium was then removed and fresh medium was added either alone or supplemented with different concentrations of the "plant complex" product 0.1%, 0.2%, 0.5%, 1% and 5%). The contact times of the product with the cells were 24 hours.
- Radioactive precursors were added to the cultures after the incubation times with the product at different concentrations.
- the cells were then incubated for an additional two hours at 37 ° C. in the presence of 3 H-leucine (1 ⁇ Ci / ml of culture medium, specific activity: 5 Ci / mmol).
- 3 H-leucine (1 ⁇ Ci / ml of culture medium, specific activity: 5 Ci / mmol).
- the cells were washed twice with serum-free medium to remove unincorporated radioactivity and then detached from the support by scratching the culture surface.
- the cells were washed again and then centrifuged at 600 g for 5 minutes.
- the cell pellet was taken up in 500 ⁇ l of medium.
- radioactivity For the determination of the radioactivity incorporated into the macromolecules, 500 ⁇ l of 20% (w / v) NaOH were added, and then the whole was subjected to hydrolysis for 30 minutes at 37 ° C. The hydrolysates were then precipitated. with 1 ml of a 40% trichloroacetic acid (TCA) solution. The preparations are left for one hour at 40 ° C. The samples were filtered on a fiberglass filter (Whatman GF / A) mounted in Millipore apparatus. The filters were washed three times with 10 ml of 5% TCA and twice with 95% ethanol and then introduced into counting flasks and dried for 30 minutes at 80 ° C. The radioactivity was measured in a counter.
- TCA trichloroacetic acid
- fibroblasts were used in large numbers to have a sufficient amount of proteoglycans and glycosaminoglycans.
- the fibroblasts were distributed in multiwell wells (6 wells) at a rate of 2.10 5 / ml in 3 ml of culture medium. They were then kept for 24 hours in CO 2 ovens.
- the pulsation technique was adopted. The radioactive precursor ([3H] - Glucosamine) was added to the cultures 18 hours before cell recovery.
- the contact time of the cells with the product was 24 hours at 37 ° C. After removing the medium by suction, the cells were washed twice with serum-free medium to eliminate the unincorporated radioactivity, and then detached from the support. by scratching the surface of the crop. The cells were washed again with medium and then recentrifuged at 600 g for 5 minutes. From this final pellet were made: - the proteoglycan assay by FPLC (Fast Protein Liquid Chromatography) - the neosynthesis of total glycosaminoglycans (GAGs) - the total protein assay
- Perimembrane Proteoglycans A first fraction of the pellet was resuspended in 1M NaCl containing deoxyribonuclease (50 U / ml) and protease inhibitors. The homogenate was then incubated at 4 ° C for 2 hours. Centrifugation for 30 minutes at 12,000 g allowed to obtain the first homogenate containing peri-membrane proteoglycans. The pellet was used to extract the proteoglycans from the other 2 compartments (Cl).
- Matrix proteoglycans The C2 pellet was washed three times with 0.1% sodium azide and then resuspended with stirring in a 50 mM sodium acetate buffer containing 4 M guanidine HCl and triton X-100 0, 1% as well as protease inhibitors. Centrifugation for 30 minutes at 12,000 g yielded the third supernatant containing the matrix proteoglycans.
- each of the 3 supernatants was precipitated overnight at 40 ° C. in a volume of absolute ethanol and then centrifuged at 12,000 g for 30 minutes. The pellets obtained were resuspended in a 5mM Tris-HCl buffer pH 7.4. The same analysis protocol was performed for 3 solutes. Anion exchange chromatography was used. Each pellet was resuspended in 250 ml of 50 mM Tris-HCl buffer pH 7.4. Sepharose gel CL-6B (DEAE) (Pharmacia) was cast in a K 10/40 column (Pharamcia). The anion exchange gel has a high resolution and a good yield. 100 ⁇ l of each sample were injected; Elution is monitored by 280 nm wavelength spectrofluorometer detection. The peak containing the proteoglycans is eluted at 1 M NaCl. dosage
- the radioactivity assay is performed at the HPLC outlet using a Packard meter (Flow-one).
- fibroblasts were cultured in the same way as in section 1.4.1. After the incubation time, the fibroblasts are recovered by centrifugation. The pellets are digested with collagen (1 mg / cell pellet) in acetic acid 0.5 ml / 1 for 24 hours at 4 ° C. After centrifugation at 10,000 g, the collagens are precipitated by sodium chloride ( 1M NaCl), the precipitate is resuspended and then dialyzed. The primary amino acids are derived by ophthaldehyde acid (OPA) thus eliminating their interference.
- OPA ophthaldehyde acid
- NBD-Cl Hydroxyproline and proline are then derived by NBD-Cl by coupling of the amino groups to NBD-Cl.
- the NBD-Hyp is separated and identified by reverse phase HPLC.
- a coupling to the NBD-CL of a standard containing the hydroxyproline is first carried out.
- - Hydroxyproline is measured by fluorescence measurement after reverse phase HPLC separation: o Automatic injector o Ultrasep C18 column (30cm * 0.18cm) o 6 ⁇ m porosity o Fluorescence detector
- the mobile phase consists of a mixture of acetonitrile / 0.1 mol / l sodium phosphate buffer, pH 7.2 (9:91 v / v), the flow rate is set to 1 ml / min, the elution is carried out in static mode and the cycle is 10 minutes.
- the mobile phase is filtered beforehand and degassed before use.
- the standard range is prepared from a 50 mg / l hydroxyproline solution. Successive dilutions make it possible to obtain solutions ranging from 0.5 to 40 mg / l.
- Derivatization and establishment of the calibration curve are performed from 10 .mu.l of a standard solution at different concentrations mixed with 10 .mu.l of the buffer.
- the tubes After addition of 5 ⁇ l of OPA and stirring, the tubes are kept for 5 min at ambient temperature and then 10 ⁇ l of the NBD-Cl solution are added. The derivate is at 60 ° C in a water bath for 3 minutes, protected from light. The tubes are then removed and the orange color makes it possible to check the derivatization. They are then put in the ice to ensure cooling. 50 ⁇ l of this mixture are then injected into the column in order to obtain the calibration curve which must be linear. The samples are treated in the same way.
- MMP-3 Metalloproteinase 3 Detection Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0406003A FR2871058B1 (fr) | 2004-06-03 | 2004-06-03 | Association a base d'extraits vegetaux et composition topique la contenant |
PCT/FR2005/001346 WO2006000689A1 (fr) | 2004-06-03 | 2005-06-01 | Association d'extraits vegetaux a base de groseille maquereau, d’orchidee noire et de tulipe noire et composition topique comprenant l’association de ces extraits vegetaux |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1830787A1 true EP1830787A1 (fr) | 2007-09-12 |
Family
ID=34948698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05775497A Withdrawn EP1830787A1 (fr) | 2004-06-03 | 2005-06-01 | Association d'extraits vegetaux à base de groseille maquereau, d'orchidee noire et de tulipe noire et composition topique comprenant l'association de ces extraits végétaux |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080020077A1 (fr) |
EP (1) | EP1830787A1 (fr) |
CA (1) | CA2566905A1 (fr) |
FR (1) | FR2871058B1 (fr) |
WO (1) | WO2006000689A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20055644A0 (fi) | 2005-12-02 | 2005-12-02 | Nokia Corp | Ryhmäviestintä |
FR2928090B1 (fr) | 2008-03-03 | 2014-10-10 | Lvmh Rech | Utilisation d'un extrait de l'orchidee vanda coerulea comme agent hydratant de la peau |
FR2928549B1 (fr) | 2008-03-13 | 2013-07-26 | Lvmh Rech | Utilisation d'un extrait de l'orchidee brassocattleya marcella koss en tant qu'actif pour prevenir ou retarder l'apparition des signes du vieillissement cutane |
US20100068259A1 (en) * | 2008-05-30 | 2010-03-18 | Annette Tobia | Natural product inhibitors of 3dg |
FR2937533B1 (fr) * | 2008-10-29 | 2010-11-26 | Oreal | Association d'extrait d'orchidee et d'extrait de proteines de soja |
KR20160091037A (ko) * | 2015-01-23 | 2016-08-02 | (주)아모레퍼시픽 | 구스베리 추출물 또는 글루타티온을 포함하는 조성물 |
CN107267289A (zh) * | 2017-07-14 | 2017-10-20 | 新疆郁金香生物科技有限公司 | 一种郁金香精油的提取方法 |
FR3068893B1 (fr) * | 2017-07-17 | 2021-02-19 | Caster | Extrait de tulipe |
CN108272727A (zh) * | 2018-04-08 | 2018-07-13 | 上海粉蝶化妆品有限公司 | 一种雨百合肉唇兰面霜 |
US20220142910A1 (en) * | 2020-11-06 | 2022-05-12 | Dianne Martin Bastian | Composition including all natural botanical peptide ingredients for topical skin applications |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02279618A (ja) * | 1989-04-20 | 1990-11-15 | Ichimaru Pharcos Co Ltd | ラン科植物抽出物含有化粧料 |
FR2699818B1 (fr) * | 1992-12-24 | 1995-02-03 | Oreal | Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko. |
JP3805022B2 (ja) * | 1996-06-20 | 2006-08-02 | 株式会社ノエビア | 皮膚外用剤 |
ES2367523T3 (es) * | 1999-08-26 | 2011-11-04 | Jean Julia | Composición cosmética que contiene aceites de cynara cardunculus o de silybum marianum. |
FR2804864B1 (fr) * | 2000-02-11 | 2003-04-04 | Serobiologiques Lab Sa | Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie |
US20040175439A1 (en) * | 2001-03-02 | 2004-09-09 | Benoit Cyr | Plant extracts and compositions comprising extracellular protease inhibitors |
WO2002069921A1 (fr) * | 2001-03-07 | 2002-09-12 | Unilever Plc | Compositions de coloration capillaire |
JP2003040758A (ja) * | 2001-07-25 | 2003-02-13 | Matsukawa Kagaku:Kk | 化粧料 |
US20040133956P1 (en) * | 2003-01-03 | 2004-07-08 | Jury Mark C. | Magnolia plant named 'JURmag1' |
JP2004269430A (ja) * | 2003-03-10 | 2004-09-30 | Ichimaru Pharcos Co Ltd | 毛髪処理用組成物及び損傷毛用毛髪化粧料 |
-
2004
- 2004-06-03 FR FR0406003A patent/FR2871058B1/fr not_active Expired - Fee Related
-
2005
- 2005-06-01 CA CA002566905A patent/CA2566905A1/fr not_active Abandoned
- 2005-06-01 WO PCT/FR2005/001346 patent/WO2006000689A1/fr active Application Filing
- 2005-06-01 EP EP05775497A patent/EP1830787A1/fr not_active Withdrawn
- 2005-06-01 US US11/628,233 patent/US20080020077A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2006000689A1 * |
Also Published As
Publication number | Publication date |
---|---|
FR2871058A1 (fr) | 2005-12-09 |
WO2006000689A1 (fr) | 2006-01-05 |
CA2566905A1 (fr) | 2006-01-05 |
US20080020077A1 (en) | 2008-01-24 |
FR2871058B1 (fr) | 2006-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1830787A1 (fr) | Association d'extraits vegetaux à base de groseille maquereau, d'orchidee noire et de tulipe noire et composition topique comprenant l'association de ces extraits végétaux | |
FR2975495A1 (fr) | Methode de criblage de principes actifs favorisant la deglycation des ages | |
EP2691074A1 (fr) | Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau | |
EP3980124B1 (fr) | Extrait du tourteau des graines de moringa peregrina, son procédé d'obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques | |
EP2046281B1 (fr) | Utilisation d'un extrait de graines de mimosa (d'acacia dealbta, d'acacia farnesiana ou d'acacia decurrens) dans une composition cosmetique | |
WO2015049268A1 (fr) | Utilisation d'une composition huileuse contenant un extrait d'hemerocalle pour ameliorer la fermete de la peau | |
FR2948877A1 (fr) | Composition pour la protection et la regeneration de la peau | |
EP2046356B1 (fr) | Utilisation d'un extrait de gleditsia en cosmétique et en dermatologie | |
EP2699227B1 (fr) | Complexe d'extraits végétaux pour la protection de la peau. | |
FR3030273A1 (fr) | Composition comprenant un extrait de lotus, un extrait d'hamamelis et du zinc, et son utilisation cosmetique | |
EP2811977B1 (fr) | Utilisation d'un extrait de feuille de pommier dans une composition cosmetique pour le raffermissement de la peau | |
EP2811978B1 (fr) | Utilisation d'un extrait d'ecorce de pommier dans une composition cosmetique anti-age | |
FR2859102A1 (fr) | Utilisation d'un extrait de rhodiola crenulata par voie topique | |
FR2885052A1 (fr) | Utilisation d'un extrait de maca pour proteger la microcirculation cutanee | |
EP3229923B1 (fr) | Utilisation cosmétique d'un extrait d'eschscholtzia californica | |
FR2997854A1 (fr) | Utilisation d'un extrait de saba senegalensis dans une composition cosmetique anti-age | |
FR3021539A1 (fr) | Composition cosmetique et/ou dermatologique comprenant un extrait vegetal et un activateur de genes | |
FR3110346A1 (fr) | Extrait du tourteau des graines de Moringa peregrina, son procédé d’obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques | |
EP2866900A2 (fr) | Composition topique apaisante a base d'extraits de paeonia et de nymphaea | |
FR2984740A1 (fr) | Utilisation d'un extrait de ravenala en tant qu'ingredient actif cosmetique anti-age | |
WO2012172200A1 (fr) | Composition a base de samanea saman pour la protection de la peau | |
FR2885049A1 (fr) | Composition a base d'extraits de graines d'araucaria pour la protection de l'epiderme. | |
FR2997855A1 (fr) | Utilisation d'un extrait de saba senegalensis dans une composition cosmetique apaisante et/ou uniformisant la couleur de la peau | |
FR2973698A1 (fr) | Composition a base de gleditsia pour le traitement des surcharges adipeuses. | |
EP2849720A2 (fr) | Utilisation d'un extrait de gattilier pour la preparation d'une composition cosmetique et/ou dermatologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20061211 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1108649 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20080505 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MESYL LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081118 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1108649 Country of ref document: HK |